A Phase I Pharmacokinetic, Pharmacodynamic and Feasibility Study of Crenolanib in Combination With Sorafenib in Patients With Refractory or Relapsed Hematologic Malignancies (ARO-008)

Trial Profile

A Phase I Pharmacokinetic, Pharmacodynamic and Feasibility Study of Crenolanib in Combination With Sorafenib in Patients With Refractory or Relapsed Hematologic Malignancies (ARO-008)

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Oct 2017

At a glance

  • Drugs Crenolanib (Primary) ; Cytarabine; Hydrocortisone; Methotrexate; Sorafenib
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 02 Oct 2017 Status changed from active, no longer recruiting to completed.
    • 06 Dec 2016 Results (n=7) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
    • 03 Nov 2016 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top